Amgen welcomes European Commission report on EU biosimilars uptake

May 2, 2013 10:40 AM

Amgen, a biotechnology company developing both innovative biologic and biosimilar medicines, welcomes a new report from the European Commission detailing Europe’s strong regulatory and commercial foundation for biosimilars in the healthcare marketplace.

The report shows that biosimilars are helping improve competition and thus may be increasing access to biologic medicines for patients.

The science-led regulatory framework in the European Union (EU) has established confidence in biosimilars which has allowed for these therapeutic alternatives to successfully enter into clinical practice. As governments, industry and the healthcare sector work together to improve health outcomes, the report reaffirms that protecting patient safety is the cornerstone of the EU’s regulatory framework for biosimilar medicines.

Amgen, a core stakeholder in the consultation process for this report, welcomes the opportunity this consensus document provides for ongoing balanced and informed discussions on the European biosimilars experience.

The report is designed to help national governments, health care professionals and patients make informed choices on the role current and future biosimilar medicines may have in achieving optimal healthcare outcomes.

The EC report can be accessed from here.

Source: The Sacremento Bee, Amgen Canada

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)

Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!